Last updated
UCB: Capital Raising
UCB invested £500m in R&D hub in Surrey focused on developing medicines for immunological diseases
Source: UKTN (UK Tech News)
The leadership read
UCB's raise resets the leadership agenda more than the balance sheet. Capital into Biotech & Pharma buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across Oceania.
Market context: Backdrop: a 104.6 (Hot) Talent Market Index (down 1.9 on the month) with Oceania activity steady (+1.1pts).
UCB: 2 signals in the last 90 days — above the Biotech & Pharma median of 1 across 24 tracked companies; 0.2% of MitchelLake's EMEA signal flow; 4 tracked across 80 days.
MitchelLake in this thematic
Also at UCB →
More signals across Biotech & Pharma
Ma Activity · Oceania
Teva Pharmaceuticals →Active litigation against Eli Lilly with appeals court victory reviving lawsuit. Teva won the ability to challenge Lilly's FDA exclusivity extension that delayed its generic Forteo launch. Large-scale legal battle ongoing with significant business implications.
Partnership · Oceania
AusBiotech →AusBiotech announced a strategic partnership with Tenmile venture capital firm to strengthen ecosystem connections and help Australian health startups access both domestic and international capital. The partnership extends prior collaboration on the Early Stage Innovation Forum and creates additional opportunities for startups and scale-ups.
Capital Raising · Americas
Ratio Therapeutics →Ratio Therapeutics closed a Series C funding round of $70M for radiopharmaceutical trials, led by existing investors Duquesne Family Office and Bristol Myers Squibb, with new investor participation.
Capital Raising · Americas
BridgeBio →BridgeBio secured funding to support drug launch; United Airlines made an investment into the cell therapy space
Capital Raising · Americas
Twist Bioscience →Twist Bioscience filed an omnibus shelf registration and registered a $200M at-the-market (ATM) follow-on equity offering of common shares in June 2026.
Capital Raising · Americas
Sana Biotechnology, Inc. →Schedule 13G filing indicates potential significant ownership change or investment activity
Intelligence powered by Autonodal ↗